Ligand Pharma (LGDN) Stock Statistics & Valuation Metrics

Ligand Pharma has a market cap or net worth of CHF5.23B. The enterprise value is $5.61B.

Ligand Pharma has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Ligand Pharma’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 2.42%.

The current PE Ratio of Ligand Pharma is 40.1. Ligand Pharma’s PEG ratio is -0.00970.

In the last 12 months, Ligand Pharma had revenue of 268.09M and earned 124.45M in profits. Earnings per share was 6.44.

In the last 12 months, operating cash flow was 123.42M and capital expenditures -466.00K, giving a free cash flow of 122.96M billion.

Ligand Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Ligand Pharma upcoming earnings date is Aug 11, 2026, After Close (Confirmed).

Ligand Pharma as a current ratio of 22.23, with Debt / Equity ratio of 45.32%

In the past 12 months, Ligand Pharma has paid 34.51M in taxes.

Ligand Pharma EV to EBITDA ratio is 20.41, with an EV/FCF ratio of 80.41.

Ligand Pharma has CHF779.40M in cash and marketable securities with CHF451.98M in debt, giving a net cash position of CHF327.43M billion.

Gross margin is 98.61%, with operating margin of 17.61%, and net profit margin of 46.42%.

The average price target for Ligand Pharma is CHF250.77, which is 11.43% higher than the current price. The consensus rating is Strong Buy